CA2266619A1 - Non-invasive administration of adeno-associated viral vectors - Google Patents

Non-invasive administration of adeno-associated viral vectors Download PDF

Info

Publication number
CA2266619A1
CA2266619A1 CA002266619A CA2266619A CA2266619A1 CA 2266619 A1 CA2266619 A1 CA 2266619A1 CA 002266619 A CA002266619 A CA 002266619A CA 2266619 A CA2266619 A CA 2266619A CA 2266619 A1 CA2266619 A1 CA 2266619A1
Authority
CA
Canada
Prior art keywords
aav
gene
vector
interest
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002266619A
Other languages
English (en)
French (fr)
Inventor
Richard Snyder
James Mcarthur
Olivier Danos
Richard Mulligan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Genesys Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2266619A1 publication Critical patent/CA2266619A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002266619A 1996-09-25 1997-09-25 Non-invasive administration of adeno-associated viral vectors Abandoned CA2266619A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2663896P 1996-09-25 1996-09-25
US60/026,638 1996-09-25
PCT/US1997/016929 WO1998013070A1 (en) 1996-09-25 1997-09-25 Non-invasive administration of adeno-associated viral vectors

Publications (1)

Publication Number Publication Date
CA2266619A1 true CA2266619A1 (en) 1998-04-02

Family

ID=21832986

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002266619A Abandoned CA2266619A1 (en) 1996-09-25 1997-09-25 Non-invasive administration of adeno-associated viral vectors

Country Status (6)

Country Link
EP (1) EP0928202A4 (de)
JP (1) JP2001501819A (de)
KR (1) KR20000048623A (de)
AU (1) AU743335B2 (de)
CA (1) CA2266619A1 (de)
WO (1) WO1998013070A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE486614T1 (de) * 1997-03-14 2010-11-15 Philadelphia Children Hospital Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
EP1279740A1 (de) * 2001-07-26 2003-01-29 Vrije Universiteit Brussel Von Adeno-assoziertem Virus abstammender Vektor zur Gentherapy
KR20030068337A (ko) * 2002-02-15 2003-08-21 사회복지법인삼성생명공익재단(삼성서울병원) 유전자치료용 진핵발현벡터
KR20030070702A (ko) * 2002-02-26 2003-09-02 사회복지법인삼성생명공익재단(삼성서울병원) 전기적 자극을 이용한 ｄｎａ 전달방법 및 이를 이용한 에리스로포이에틴 발현 방법
AU2019377115A1 (en) * 2018-11-07 2021-05-20 Akouos, Inc. Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear
CN115161289B (zh) * 2022-03-14 2023-12-05 东南大学 一种用于炎症性疾病治疗的重组腺相关病毒及其构建方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
FR2716682B1 (fr) * 1994-01-28 1996-04-26 Centre Nat Rech Scient Procédé de préparation de virus adéno-associés (AAV) recombinants et utilisations.
WO1995027494A1 (en) * 1994-04-11 1995-10-19 Sloan-Kettering Institute For Cancer Research DEFECTIVE HERPES AND DEFECTIVE ADENO-ASSOCIATED VIRUS VECTORS WITH p53 FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
AU743335B2 (en) 2002-01-24
EP0928202A4 (de) 2001-09-05
KR20000048623A (ko) 2000-07-25
AU4736797A (en) 1998-04-17
EP0928202A1 (de) 1999-07-14
WO1998013070A1 (en) 1998-04-02
JP2001501819A (ja) 2001-02-13

Similar Documents

Publication Publication Date Title
CA2223837C (en) Aav transduction of myoblasts
US20020172663A1 (en) Localized myocardial injection method for treating ischemic myocardium
AU2003225910A1 (en) Raav vector compositions and methods for the treatment of choroidal neovascularization
CA2319664A1 (en) Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
US20110044947A1 (en) Methods of treating cardiac disorders
EA036051B1 (ru) РЕКОМБИНАНТНЫЙ АДЕНОАССОЦИИРОВАННЫЙ ВЕКТОР (rAAV), СПОСОБНЫЙ ПРОНИКАТЬ СКВОЗЬ ГЕМАТОЭНЦЕФАЛИЧЕСКИЙ БАРЬЕР (ГЭБ), И ЕГО ПРИМЕНЕНИЕ ДЛЯ ВОССТАНОВЛЕНИЯ ЭКСПРЕССИИ Glut1
US6989374B1 (en) Gene therapy for cardiomyopathy
CN113563430A (zh) 用于治疗眼部疾病的基因递送系统及其应用
AU743335B2 (en) Non-invasive administration of adeno-associated viral vectors
AU763049B2 (en) Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors
KR20010108053A (ko) 당뇨병성 허혈성 질환 유전자 치료
AU737129B2 (en) Long-term expression of gene products by transforming muscle cells
JP2002522558A (ja) エリスロポエチンをコードするアデノウイルスベクター及び遺伝子治療におけるそれらの使用
US7196062B2 (en) Method for treating glaucoma
KR20240063110A (ko) 치료제의 역행성 관상 정맥 또는 정맥동 투여
US20210269508A1 (en) Methods for regulating endogenous production of lactoferrin and sub-peptides thereof
WO2024094009A1 (zh) 用于目的基因的表达盒及其应用
AU758530B2 (en) Delivery of multiple genes to cells using plural adeno-associated viral vectors
AU763063B2 (en) AAV transduction of myoblasts
WO2008130949A2 (en) Modulating nurr1 expression in a cell
JP2001335489A (ja) 核酸導入製剤

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead